EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Jinlida for Diabetes Prevention in Impaired Glucose Tolerance and Multiple Metabolic Abnormalities

Hangyu Ji, Xuefei Zhao, Xinyan Chen, Hui Fang, Huailin Gao, Geng Wei, Min Zhang, Hongyu Kuang, Baijing Yang, Xiaojun Cai, Yanjin Su, Chunli Piao und 18 weitere

JAMA Internal Medicine · 01.07.2024 · 184 (7) · 727

DOI: 10.1001/jamainternmed.2024.1190 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Internal Medicine, erschienen am 01.07.2024. Verfasst von Hangyu Ji und 29 weiteren Autor:innen. Beteiligte Einrichtung: Good Clinical Practice Office, Guang'anmen Hospital China Academy of Chinese Medical Sciences, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Drugs, Chinese Herbal, Glucose Intolerance. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Previous studies have shown that Jinlida (JLD) granules, an approved treatment for type 2 diabetes in China, can reduce blood glucose level, reduce glycated hemoglobin (HbA 1c ), and improve insulin resistance in people with type 2 diabetes.

Objective

To evaluate the effect of long-term administration of JLD vs placebo on the incidence of diabetes in participants with impaired glucose tolerance (IGT) and multiple metabolic abnormalities. Design, Setting, and Participants This multicenter, double-blind, placebo-controlled randomized clinical trial (FOCUS) was conducted across 35 centers in 21 cities in China from June 2019 to February 2023. Individuals aged 18 to 70 years with IGT and multiple metabolic abnormalities were enrolled.

Intervention

Participants were randomly allocated 1:1 to receive JLD or placebo (9 g, 3 times per day, orally). They continued this regimen until they developed diabetes, withdrew from the study, were lost to follow-up, or died. Main Outcomes and Measures The primary outcome was the occurrence of diabetes, which was determined by 2 consecutive oral glucose tolerance tests. Secondary outcomes included waist circumference; fasting and 2-hour postprandial plasma glucose levels; HbA 1c ; fasting insulin level; homeostatic model assessment for insulin resistance (HOMA-IR); total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels; ankle-brachial index; and carotid intima-media thickness.

Results

A total of 889 participants were randomized, of whom 885 were in the full analysis set (442 in the JLD group; 443 in the placebo group; mean [SD] age, 52.57 [10.33] years; 463 [52.32%] female). Following a median observation period of 2.20 years (IQR, 1.27-2.64 years), participants in the JLD group had a lower risk of developing diabetes compared with those in the placebo group (hazard ratio, 0.59; 95% CI, 0.46-0.74; P < .001). During the follow-up period, the JLD group had a between-group difference of 0.95 cm (95% CI, 0.36-1.55 cm) in waist circumference, 9.2 mg/dL (95% CI, 5.4-13.0 mg/dL) in 2-hour postprandial blood glucose level, 3.8 mg/dL (95% CI, 2.2-5.6 mg/dL) in fasting blood glucose level, 0.20% (95% CI, 0.13%-0.27%) in HbA 1c , 6.6 mg/dL (95% CI, 1.9-11.2 mg/dL) in total cholesterol level, 4.3 mg/dL (95% CI, 0.8-7.7 mg/dL) in low-density lipoprotein cholesterol level, 25.7 mg/dL (95% CI, 15.9-35.4 mg/dL) in triglyceride levels, and 0.47 (95% CI, 0.12-0.83) in HOMA-IR compared with the placebo group. After 24 months of follow-up, the JLD group had a significant improvement in ankle-brachial index and waist circumference compared with the placebo group. Conclusions and Relevance The findings suggest that JLD can reduce the risk of diabetes in participants with IGT and multiple metabolic abnormalities. Trial Registration Chinese Clinical Trial Register: ChiCTR1900023241

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Drugs, Chinese HerbalGlucose IntoleranceAdultAgedFemaleHumansMaleMiddle AgedBlood GlucoseChinaDouble-Blind MethodGlucose Tolerance TestGlycated HemoglobinInsulin Resistance

Substanzen

Blood GlucoseDrugs, Chinese HerbalGlycated Hemoglobinjinlida

Autor:innen und Institutionen

  • Good Clinical Practice Office, Guang'anmen Hospital China Academy of Chinese Medical Sciences, Beijing, China.
  • Department of Endocrinology, Guang'anmen Hospital China Academy of Chinese Medical Sciences, Beijing, China.
  • Department of Prevention and Treatment of Disease, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China.
  • Department of Endocrinology, Tangshan Gongren Hospital, Tangshan, China.
  • Department of Endocrinology, Hebei Yiling Hospital, Shijiazhuang, China.
  • Department of Traditional Chinese Medicine, Shijiazhuang 2nd Hospital, Shijiazhuang, China.

Zitieren

APA

Ji, H., Zhao, X., Chen, X., Fang, H., Gao, H., Wei, G., Zhang, M., Kuang, H., Yang, B., Cai, X., Su, Y., Piao, C., Zhao, S., Li, L., Sun, W., Xu, T., Xu, Q., Fan, Y., Ye, J., …, & FOCUS Trial Committees and Investigators (2024). Jinlida for Diabetes Prevention in Impaired Glucose Tolerance and Multiple Metabolic Abnormalities. JAMA Internal Medicine, 184(7), 727. https://doi.org/10.1001/jamainternmed.2024.1190

Vancouver

Ji H, Zhao X, Chen X, Fang H, Gao H, Wei G, et al. Jinlida for Diabetes Prevention in Impaired Glucose Tolerance and Multiple Metabolic Abnormalities. JAMA Internal Medicine. 2024;184(7):727. doi:10.1001/jamainternmed.2024.1190

BibTeX
@article{Ji2024,
  author = {Ji, Hangyu and Zhao, Xuefei and Chen, Xinyan and Fang, Hui and Gao, Huailin and Wei, Geng and Zhang, Min and Kuang, Hongyu and Yang, Baijing and Cai, Xiaojun and Su, Yanjin and Piao, Chunli and Zhao, Shuyu and Li, Liyang and Sun, Wenliang and Xu, Tianshu and Xu, Qinghua and Fan, Yuan and Ye, Jianhua and Yao, Chen and Shang, Meixia and Song, Guangyao and Chen, Liming and Zheng, Qingshan and Xiao, Xinhua and Yan, Li and Lian, Fengmei and Tong, Xiaolin and Jia, Zhenhua and FOCUS Trial Committees and Investigators, FOCUS Trial Committees and Investigators},
  title = {Jinlida for Diabetes Prevention in Impaired Glucose Tolerance and Multiple Metabolic Abnormalities},
  journal = {JAMA Internal Medicine},
  year = {2024},
  volume = {184},
  number = {7},
  pages = {727},
  doi = {10.1001/jamainternmed.2024.1190}
}
Kostenlos starten →